ストックスクリーナーアプリを入手
1.825
0.83%
0.015
Gain Therapeutics Inc (GANX) 最新ニュース
Enterprise value to EBIT forward of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
GANX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
H.C. Wainwright reiterates Gain Therapeutics stock rating on FDA approval - Investing.com
Gain Therapeutics Buy Rating Reiterated as FDA Clears GT-02287 Phase 2; 12-Month $8 Price Target Maintained - TipRanks
Price to sales forward of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Number of shareholders of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Gain Therapeutics Receives FDA Clearance to Initiate Phase 2 Trial of GT-02287 for Parkinson’s Disease - Minichart
Stocks to Watch: AeroVironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines - Moomoo
Why Is GANX Stock Rallying 22% After Hours? - Asianet Newsable
Gain Therapeutics stock surges on FDA clearance for Parkinson’s drug By Investing.com - Investing.com India
Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial - TipRanks
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Gain Therapeutics Gets US FDA Approval to Advance GT-02287 Into Phase 2 Study for Parkinson's Disease - marketscreener.com
Gain Therapeutics stock surges on FDA clearance for Parkinson’s drug - Investing.com
Gain Therapeutics receives FDA clearance for Parkinson’s drug trial - Investing.com
Gain Therapeutics (GANX) wins FDA IND clearance to start GT-02287 Phase 2 Parkinson’s trial - Stock Titan
Gain Therapeutics receives FDA clearance for Parkinson’s drug trial By Investing.com - Investing.com India
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease - The Manila Times
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 Into Phase 2 Development for Parkinson's Disease - Moomoo
FDA clears Gain Therapeutics drug GT-02287 for Phase 2 Parkinson’s trial - Stock Titan
Price to earnings forward of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Gain Therapeutics Inc (GANX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gain Therapeutics, Inc. Announces 2026 Shareholder Vote Results and Emerging Growth Company Status (GANX) - Minichart
Gain Therapeutics, Inc. Actuals & Estimates (NASDAQ:GANX) - TradingView
Gain Therapeutics Shareholders Confirm Board and Auditor Choices - TipRanks
Gain Therapeutics (GANX) shareholders back board slate and Ernst & Young AG at 2026 meeting - Stock Titan
GANX Forecast — Price Target — Prediction for 2027 - TradingView
3 Clinical-Stage Biotech Stocks Worth Watching In Parkinson's Research - Sahm
Gain Therapeutics Inc (GANX) Institutional Confidence - TradingKey
Gain Therapeutics Inc (GANX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Gain Therapeutics Inc (GANX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gain Therapeutics Inc (GANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GAIN THERAPEUTICS INC (GANX) Stock Chart - ChartMill
Gain Therapeutics Inc (GANX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Gain Therapeutics Inc (GANX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Gain Therapeutics Inc (GANX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gain Therapeutics Inc (GANX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Viking Therapeutics, Inc. (VKTX) gains as market dips: What you should know - MSN
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know - Yahoo Finance
Gain Therapeutics Inc. (GANX) Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesRevenue Guidance Range - newsline.com
GANX Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - The Manila Times
Biotech Gain Therapeutics joins H.C. Wainwright Neuro expert summit - Stock Titan
Bial Ends Development Of Parkinson’s Disease Drug After Phase IIb Fail - Citeline News & Insights
Niemann-Pick Type Pipeline Gains Momentum: 10+ Companies Lead - openPR.com
Which stocks are moving after the closing bell on Monday? - ChartMill
Dyne Therapeutics (DYN) investors double share authorization and approve all proposals - Stock Titan
TVTX: FILSPARI cements its role in rare kidney disease, with robust growth and pipeline innovation - TradingView
Tango Therapeutics Shares Surge 32% on Strong Clinical Momentum in Precision Oncology - International Business Times Australia
Monday's pre-market session: top gainers and losers - ChartMill
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
OPKO Health (OPK) Amends Partnership With Nicoya Therapeutics to Gain Equity Stake - Insider Monkey
Gain Therapeutics (GANX) price target increased by 11.76% to 7.75 - MSN
4 Biotech Stocks Investors Should Watch in 2026 - TradingView
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s? - TradingView
Eos SENOLYTIX Presents Best-in-Class Preclinical Body Composition Data Highlighting Unique Muscle Mass Gains with MitoXcel™ Geropeptide PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic... - markets.businessinsider.com
Wondering what's happening in today's pre-market session? - ChartMill
GANX Q1 2026 Earnings: Positive EPS Surprise Amidst Pre-Revenue StageHealthcare Earnings Report - newsline.com
Protagonist Therapeutics Jumps 6.1% Amid Sector-Wide Rally - AlphaStreet
All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy - Yahoo Finance
Halozyme Therapeutics Jumps 5.4% Amid Sector-Wide Rally - AlphaStreet
Navitas Semiconductor, Abivax, MiniMed And Other Big Stocks Moving Higher On Wednesday - Benzinga
TG Therapeutics Surges 10.2% Amid Sector-Wide Rally - AlphaStreet
1.60%
3.59%
大文字化:
|
ボリューム (24 時間):